Latest Depression News

Page 8 of 14
An application to the Takeovers Panel questions the integrity of Maronan Metals’ recent $16 million placement and its share purchase plan, raising concerns about undisclosed relationships and share price manipulation.
Maxwell Dee
Maxwell Dee
28 Oct 2025
Coronado Global Resources has filed a detailed SEC Form 8-K revealing confidential discussions with noteholders and outlining its growth trajectory, liquidity management, and operational updates across its Australian and US metallurgical coal assets.
Maxwell Dee
Maxwell Dee
28 Oct 2025
Emyria reports strong revenue growth driven by expanded insurer-funded mental health programs, marking a significant step in national access to evidence-based PTSD and treatment-resistant depression care.
Ada Torres
Ada Torres
27 Oct 2025
Actinogen Medical has fast-tracked enrolment in its pivotal Alzheimer’s trial, secured a clear FDA regulatory path, and strengthened its financial position with funding extending its runway to mid-2026.
Ada Torres
Ada Torres
23 Oct 2025
TrivarX has completed recruitment of 60 patients in its US veteran-focused mental health trial, advancing validation of its novel single-lead ECG algorithm for depression screening. Positive interim results from 27 patients set the stage for full data release and commercial discussions.
Ada Torres
Ada Torres
22 Oct 2025
Actinogen Medical has received approval for an additional $1.87 million research and development tax rebate, bringing its total FY25 rebate to $7.36 million. This funding underpins ongoing clinical trials of its Alzheimer’s and depression therapy candidate, Xanamem.
Ada Torres
Ada Torres
20 Oct 2025
Actinogen Medical has fast-tracked recruitment in its XanaMIA Alzheimer’s trial, closing pTau biomarker screening early and increasing participant numbers, aiming for final results by mid Q4 2026.
Ada Torres
Ada Torres
20 Oct 2025
Cogstate Limited reports a record-breaking quarter with sales contracts soaring 88% year-on-year, driven by expanding markets and new therapeutic areas. The company signals continued investment in growth initiatives, including AI and Asia-Pacific expansion, while projecting a strong first half of FY26.
Ada Torres
Ada Torres
16 Oct 2025
Emyria has secured a multi-year funding extension with Medibank to launch its Empax mental health programs in Brisbane, marking a key step in its national expansion. This insurer-backed initiative aims to improve access to treatment for complex conditions like treatment-resistant depression and PTSD.
Ada Torres
Ada Torres
15 Oct 2025
Actinogen Medical has secured an initial $5.5 million R&D tax incentive rebate from the Australian Tax Office, with an additional $1.9 million pending, bolstering funding for its Alzheimer’s and depression drug trials.
Ada Torres
Ada Torres
15 Oct 2025
Tryptamine Therapeutics has enrolled the first patient in its pioneering clinical trial testing TRP-8803, an IV-infused psilocin formulation, for Binge Eating Disorder. The study aims to evaluate safety and efficacy, potentially reshaping treatment options for millions.
Ada Torres
Ada Torres
14 Oct 2025
OD6 Metals has initiated Phase 2 drilling at its Gulf Creek Copper Project in NSW, aiming to explore large geophysical anomalies and untested prospects that could expand on previously confirmed high-grade copper mineralisation.
Maxwell Dee
Maxwell Dee
14 Oct 2025

Browse the archive

Full archive